Similar articles

• Tacrolimus to cyclosporine microemulsion formulation conversion in the pediatric liver transplant patient.

  Falkenstein K, Dunn S. Falkenstein K, et al. Transplant Proc. 1998 Aug;30(5):1964-6. doi: 10.1016/s0041-1345(98)00497-7. Transplant Proc. 1998. PMID: 9723354 No abstract available.
• Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients.

  Melter M, Rodeck B, Kardorff R, Hoyer PF, Maibücher A, Brodehl J. Melter M, et al. Transplant Proc. 1996 Aug;28(4):2276-8. Transplant Proc. 1996. PMID: 8769224 No abstract available.
• Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients.

  Lagget M, Marzano A, Actis GC, Leone N, Ciancio A, Salizzoni M, Rizzetto M. Lagget M, et al. Transplant Proc. 1998 Aug;30(5):1863-4. doi: 10.1016/s0041-1345(98)00461-8. Transplant Proc. 1998. PMID: 9723312 No abstract available.
• New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine.

  Armstrong VW, Oellerich M. Armstrong VW, et al. Clin Biochem. 2001 Feb;34(1):9-16. doi: 10.1016/s0009-9120(00)00175-2. Clin Biochem. 2001. PMID: 11239509 Review.
• Evolution of immunosuppression in liver transplantation: contribution of cyclosporine.

  Furukawa H, Todo S. Furukawa H, et al. Transplant Proc. 2004 Mar;36(2 Suppl):274S-284S. doi: 10.1016/j.transproceed.2004.01.023. Transplant Proc. 2004. PMID: 15041353 Review.